Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension
dc.contributor.author | Hernanz, R | |
dc.contributor.author | Martínez-Revelles, S | |
dc.contributor.author | Palacios-Ramírez, R | |
dc.contributor.author | Martín, A | |
dc.contributor.author | Cachofeiro, V | |
dc.contributor.author | Aguado, A | |
dc.contributor.author | García-Redondo, L | |
dc.contributor.author | Barrús, MT | |
dc.contributor.author | de Batista, PR | |
dc.contributor.author | Briones, AM | |
dc.contributor.author | Salaices, M | |
dc.contributor.author | Alonso, MJ | |
dc.date.accessioned | 2024-07-08T11:45:31Z | |
dc.date.available | 2024-07-08T11:45:31Z | |
dc.date.issued | 2015-02-17 | |
dc.identifier.citation | Hernanz, R., Martínez-Revelles, S., Palacios, R., Martín, A., Cachofeiro, V., Aguado, A., García-Redondo, L., Barrús, M.T., de Batista, P.R., Briones, A.M., Salaices, M. and Alonso, M.J. (2015), TLR4 and vascular damage in hypertension. Br J Pharmacol, 172: 3159-3176. https://doi.org/10.1111/bph.13117 | es |
dc.identifier.issn | 0007-1188 (print) | |
dc.identifier.issn | 1476-5381 (online) | |
dc.identifier.uri | https://hdl.handle.net/10115/37109 | |
dc.description.abstract | Toll-like receptor 4 (TLR4) signalling contributes to inflammatory cardiovascular diseases, but its role in hypertension and the associated vascular damage is not known. We investigated whether TLR4 activation contributed to angiotensin II (AngII)-induced hypertension and the associated vascular structural, mechanical and functional alterations. AngII was infused (1.44 mg·kg−1·day−1, s.c.) for 2 weeks in C57BL6 mice, treated with a neutralizing anti-TLR4 antibody or IgG (1 μg·day−1); systolic BP (SBP) and aortic cytokine levels were measured. Structural, mechanical and contractile properties of aortic and mesenteric arterial segments were measured with myography and histology. RT-PCR and Western blotting were used to analyse these tissues and cultured vascular smooth muscle cells (VSMC) from hypertensive rats (SHR). Aortic TLR4 mRNA levels were raised by AngII infusion. Anti-TLR4 antibody treatment of AngII-treated mice normalised: (i) increased SBP and TNF-α, IL-6 and CCL2 levels; (ii) vascular structural and mechanical changes; (iii) altered aortic phenylephrine- and ACh-induced responses; (iv) increased NOX-1 mRNA levels, superoxide anion production and NAD(P)H oxidase activity and effects of catalase, apocynin, ML-171 and Mito-TEMPO on vascular responses; and (v) reduced NO release and effects of L-NAME on phenylephrine-induced contraction. In VSMC, the MyD88 inhibitor ST-2825 reduced AngII-induced NAD(P)H oxidase activity. The TLR4 inhibitor CLI-095 reduced AngII-induced increased phospho-JNK1/2 and p65 NF-κB subunit nuclear protein expression. TLR4 up-regulation by AngII contributed to the inflammation, endothelial dysfunction, vascular remodelling and stiffness associated with hypertension by mechanisms involving oxidative stress. MyD88-dependent activation and JNK/NF-κB signalling pathways participated in these alterations. | es |
dc.language.iso | eng | es |
dc.publisher | British Pharmacological Society | es |
dc.subject | AngII, angiotensin II; DAMPs, damage-associated molecule patterns; ECM, extracellular matrix; HSP, heat shock proteins; IEL, internal elastic lamina; KHS, Krebs–Henseleit solution; ML-171, 2-acetylphenothiazine; ROS, reactive oxygen species; SBP, systolic BP; SHR, spontaneously hypertensive rats; TLR4, Toll-like receptor 4; VSMC, vascular smooth muscle cells | es |
dc.title | Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | 10.1111/bph.13117 | es |
dc.rights.accessRights | info:eu-repo/semantics/closedAccess | es |
Files in this item
This item appears in the following Collection(s)
-
Artículos de Revista [4166]
Los ítems de digital-BURJC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario